Navigation Links
ArterX™ Clinical Trial Results Announced at Veith Meeting
Date:11/18/2010

MOUNTAIN VIEW, Calif., Nov. 18, 2010 /PRNewswire/ -- US clinical trial results for Tenaxis' investigational vascular surgical sealant, ArterX, were presented today at the Veith Meeting in New York.  William M. Stone, MD of the Mayo Clinic, Scottsdale AZ reported a more than 20% margin of improvement for ArterX Surgical Sealant in the sealing of vascular suture lines compared with a control group featuring a commercially available gelatin foam/thrombin combination.

In a presentation titled "A Novel More Effective Glue-Sealant (ArterX) for Hemostasis at Vascular Suture Lines and Other Sites," Dr. Stone reported that ArterX Surgical Sealant achieved immediate hemostasis more than 60% of the time in a 217 patient clinical trial conducted at 11 different hospitals in the US.

President and CEO, David Smith, commented, "We are delighted with the preliminary results of our US clinical trial.  We were also able to show a statistically significant reduction in operating time of 36 minutes in the ArterX group, and ArterX patients were discharged from hospital after 4.1 days, an improvement of 1.3 days over the control group. If approved, we believe that ArterX Surgical Sealant will yield economic benefits for surgeons and hospitals that adopt it."

ArterX Surgical Sealant is currently under review by the FDA and is not available for sale in the USA.

ArterX is CE Marked in the European Union

About Tenaxis Medical, Inc.

Incorporated in 2004 and located in Mountain View, CA, Tenaxis Medical, Inc. is a privately held Company. It develops novel, high performance sealants for use in vascular and general surgery. In addition to the ArterX Surgical Sealant, the company is developing a second high performance sealant for use throughout the gastrointestinal tract, and an anti-adhesion agent that can be delivered  laparoscopically to help prevent or reduce pelvic and abdominal adhesions.Contact: Ronald Dieck+1-650-691-9016, ext. 110
'/>"/>

SOURCE Tenaxis Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
2. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
3. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
4. Clinical Experts Describe Radiosurgical Advances for Brain, Breast, and Spinal Cancers
5. Cylene to Present Advances with Industrys Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
6. PAREXEL Wins Clinical Research Team of the Year Scrip Award
7. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
8. HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCE
9. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
10. Frost & Sullivan Recognizes Merge Healthcares Clinical Imaging Management Solution as Game Changing Technology
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
Breaking Medicine Technology:
(Date:9/21/2017)... Payne, AL (PRWEB) , ... September 21, 2017 ... ... preparation provider with offices serving communities in northern Alabama and Georgia, is embarking ... breast cancer prevention by utilizing modern early detection methods. , US Breast ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), ... latest Artificial Intelligence (AI) thinking, announced today the launch of its revamped web ... essential information that offers a more comprehensive understanding of the organization’s business and ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... a voice for people who have kidney disease. The theme “Describe a positive ... their stories. Entrants needed to meet only one qualification— to have been ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... much-anticipated fall event , Look Awesome This Autumn with CoolSculpting®. Scheduled for ... pricing and refreshments. , Mirror Mirror Beauty Boutique is Houston’s largest ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... innovation, the company recently unveiled a redesigned website. The new site – still ... of building owners, architects, contractors and other industry users that Garland serves. , ...
Breaking Medicine News(10 mins):